anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The most expensive variable in the operating room (OR) is time. At the Faulkner hospital one hour of OR time costs approximately $500, exclusive of supply and personnel costs. Many things contribute to the amount of time a surgical procedure takes. One of these is application of the post surgical immobilization required of almost all orthopedic surgery cases. Custom molded Plaster-of-Paris splints are used for immobilization after the vast majority of orthopedic foot and ankle procedures. They have many advantages including exact fit for each patient, low cost and excellent safety profile. Traditionally these splints are constructed from bulk supplies at the end of surgical cases. The collection, measurement and organization of the component materials require the circulating nurse or surgeon to devote time to these tasks. This necessarily precludes OR staff from performing other tasks in the OR and lengthens the overall case duration. By lengthening the duration of the case more cost is incurred. The total number of cases able to be completed in a single operative day may also be diminished by the aggregate increased case time. Recently, the investigators have started utilizing prepared splint packs containing all components necessary for single plaster-of-Paris splint applications. This alternative to the traditional method of splint application has minimal expense over that incurred with traditional methods. Pilot studies have shown that the use of these splint packs diminish the time of application by 50 percent.
The method of treating obesity and targeting adipose tissue in a patient may use injection of a polycationic polymer, such as polyamidoamine (PAMAM) generation 3 (P-G3) or a PCL-g-PAMAM Denpol, that when delivered intraperitoneally, selectively targets visceral adiposity due to its high charge density. P-G3 treatment of obese mice inhibits visceral adiposity, increases energy expenditure, prevents obesity, and alleviates associated metabolic dysfunctions. The extracellular matrix of adipose tissue is enriched with glycosaminoglycans, the known biomacromolecules with the strongest negative charge. P-G3 uncouples adipocyte lipid synthesis and storage from adipocyte development, creating adipocytes with normal functions but that are deficient in hypertrophic growth. The visceral fat distribution of P-G3 is further enhanced by modifying P-G3 with cholesterol to form lipophilic nanoparticles, effective in treating obesity. This strategy provides a method to target visceral adiposity, and cationic nanomaterials useful for treating metabolic diseases or for delivery of additional treating agents.
Abiraterone and enzalutamide (AA/ENZ) are drugs which are being used to treat metastatic prostate cancer. These drugs are a form of additional hormonal therapy and have been used for many years. For most patients, these drugs work well and the prostate cancer stays under control for several months to years. In all patients, there will be a moment when the prostate cancer doesn't respond anymore to the treatment. This is called resistance. This leads to increasement of PSA, tumor growth on the CT-scan and/or bone scan or decline of condition. The investigators want to establish if it is possible to delay the development of resistance by using the drugs differently. It is now recommended to use AA/ENZ daily until the prostate cancer doesn't respond anymore to the treatment. During treatment, all cancer cells sensitive to treatment will die and all cells resistant for treatment will survive. Based on evolutionary principles, this might not be a wise strategy. The groups of resistant cancer cells will prevail and will grow faster and faster. This will lead to increasement of PSA, tumor growth on the CT-scan and/or bone scan or decline of condition. The investigators want to establish if it is better to not take the treatment drugs daily, but to pause the treatment on regular basis. The theory of the investigators is that, due to just in time pausing the treatment, a part of the treatment sensitive cells will remain alive. These treatment sensitive cancer cells will compete with the treatment resistant cells for limited space and nutrients. In this way, the treatment sensitive cancer cells prevent the accelerating growth of the treatment resistant cancer cells. Due to this phenomenon, the investigator hypothesis is the prostate cancer will respond longer to treatment. It will take longer until a new treatment is necessary or until a patients develops complaints. When the treatment is paused, patients might experience less side effects. It is easy to establish whether the prostate cancer responds to treatment by measuring PSA.
A tablet (10) for the controlled release of a drug. The tablet (10) is in the form of an asymmetrically coated tablet so that immediate release or time-delayed release times can be precisely controlled and the extended release slab may provide zero- order or first-order extended release and pulsatile release depending on the excipients used in the tablet formulations. The core (11 ) of the tablet (10) is coated with an asymmetrical coating, that is, a coating with regions (14, 15) having different properties. The coatings may include drugs in varying concentrations. Further, different regions (14, 15) of the coating may have different rates of dissolution. The core (11 ) of the tablet (10) may be provided with a constant cross-sectional area (12) along a longitudinal length of the tablet, a coating having a first region (14) with a more rapid rate of dissolution than a second region (15). The dissolution of the first region (14) exposes only the cross-sectional area (12) to the dissolution medium. The second region (15) of the coating prevents any other portion of the core (11 ) of the tablet from being exposed to the dissolution medium. Therefore, since the cross- sectional area (12) remains constant as it is dissolved, the rate of release of the drug from the core (11 ) of the tablet remains constant. The cross-sectional area (12) may be of any geometrical configuration so long as the area remains constant as the core (11 ) dissolves.
Up to 12 patients (6 men and 6 women) will be enrolled in this open-label, single-arm, tumor imaging and dosimetry study of I-124 PGN650 in solid tumors. All eligible patients who give written, informed consent and meet all inclusion criteria and no exclusion criteria, and whose laboratory results are within specified limits at the screening visit, will be enrolled. All study subjects will receive a single intravenous (IV) dose of I-124 PGN650. Study subjects will have whole body PET/CT imaging at three different timepoints with all patients having PET/CT at 0 to 60 minutes after injection of I-124 PGN650. Study subjects will then be assigned to either a 3 to 5-hour or 6 to 8-hour timepoint and either an 18 to 26 hour or 42 to 52 hour post-injection timepoint. Tumor and whole body radioactivity distribution will be measured.
Oral roflumilast is a phosphodiesterase-4 inhibitor approved for the prevention of exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. In dermatology, topical roflumilast is authorized by the US Food and Drug Administration for the treatment of plaque psoriasis and mild to moderate seborrheic dermatitis. Several studies have described the off-label use of roflumilast in dermatology, including a randomized controlled trial showing its usefulness in the treatment of psoriasis; case reports and small series have also reported successful outcomes in hidradenitis suppurativa, recurrent oral aphthosis, nummular eczema, lichen planus, and Behçet disease. Roflumilast has a favorable safety profile, similar to that of apremilast, and it is considerably cheaper than new generation drugs and even some conventional immunosuppressants. We review the pharmacokinetics and pharmacodynamics of topical and oral roflumilast and discuss potential adverse effects and both approved and off-label uses in dermatology. Roflumilast is a promising agent to consider.
Paired urine, vaginal, and clinician-collected cervical samples will be obtained from approximately 330 women aged 23-64 years referred for colposcopy and cervical biopsies due to abnormal screening result or referred for cervical excision due to treatment of CIN2+. Upon informed consent, the women will collect a first-void urine sample and a vaginal self-sample. Before colposcopy or excision, a clinician will collect a cervical sample. Among women referred for colposcopy, four cervical punch biopsies will be taken. For women referred for excision, a cone biopsy will be taken using a loop electrosurgical excision procedure. Upon arrival in the laboratory, the paired urine, vaginal and cervical samples will be HPV tested using the Cobas 4800 HPV DNA assay. Histological results will served as reference and be grouped as ≤CIN1 (normal tissue, CIN1) versus CIN2+. The performance of the six individual methylation markers and combinations thereof will be evaluated using the histological results as reference.

The primary endpoint will be the relative sensitivity and specificity of HPV testing in first-void urine, vaginal self-sample versus clinician-collected cervical samples to detect CIN2+. Non-inferiority of HPV testing between sample types will be evaluated against a margin of 90% for sensitivity and 98% for specificity. The performance of each methylation marker will be illustrated by ROC curves and assessed by the area under the curve.
PURPOSE:To quickly and easily measure the apoprotein in a specimen by using the 1st and 2nd monoclonal antibodies which recognize the apoprotein but conjugate with different antigen sections and making measurement with an immunogical reaction at 40-50 deg.C. CONSTITUTION:The immunogical reaction is effected at >=40 deg.C and <50 deg.C at the time of measuring the surface active material of the human lung in the specimen by the immunogical method using the 1st monoclonal antibody which recognizes the apoprotein of the surface active material of the human lung and the 2nd monoclonal antibody which recognizes the apoprotein but conjugates with the antigen section different from the antigen section of the 1st monoclonal antibody. The 1st antibody is preferably immobilized on a carrier. Solid phase carriers, for example, ball, beads, etc., for which a polystyrene, PE, etc. are used, are preferably used as the carrier. As to a method or means for labeling and method or means for detection, the measurement by the secondary reaction with the antiimmune globulin antibody labeled with, for example, a radioactive material, enzyme, or fluorescent material or the staphylococcus protein A is possible.
Mirtazapine Tablets USP are indicated for the treatment of major depressive disorder. The efficacy of mirtazapine in the treatment of major depressive disorder was established in six week controlled trials of outpatients whose diagnoses corresponded most closely to the Diagnostic and Statistical Manual of Mental Disorders-3rd edition (DSM-lll) category of major depressive disorder (see CLINICAL PHARMACOLOGY).

A major depressive episode (DSM-lV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation.

The effectiveness of mirtazapine in hospitalized depressed patients has not been adequately studied.

The efficacy of mirtazapine in maintaining a response in patients with major depressive disorder for up to 40 weeks following 8-12 weeks of initial open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use mirtazapine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (See CLINICAL PHARMACOLOGY).
Methods and constructs are provided for controlling processes in live animal, plant or microbial organisms via genetically engineered near-infrared light-activated or light- inactivated proteins. In embodiments, these proteins are chimeras comprised of the photosensory modules of bacteriohytochromes and output modules that possess enzymatic activity and/or ability to bind to DNA, RNA, protein. or small molecules. DNA encoding these proteins can be introduced as genes into live animals, plants or microbes, where their activities can be turned on by near-infrared light, controlled by the intensity of light, and turned off by near-infrared light or a different wavelength than the activating light. By using light-inducible proteins, one can regulate diverse cellular processes with high spatial and temporal precision, in a nontoxic manner, often using external light sources. For example, near-infrared light-activated proteins possessing nucleotidyl cyclase, protein kinase, protease, DNA-binding and RNA-binding activities can be used to control signal transduction, cell apoptosis, proliferation, adhesion, differentiation and other cell processes.
Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training.
Subjects will be administered Placebo (lactose) TID for 4 week. There will be a 2 week washout period and then subjects will be administered Sildenafil 20mg TID for 4 weeks.
Polycystic Kidney Disease (PKD) is the most common genetic disease leading to End Stage Kidney Disease (ESKD), affecting between 1 in 500-1000 individuals from every ethnic group. The autosomal dominant (ADPKD) form arises from a two-hit downregulation of proteins encoded by either PKD1 or PKD2. Although many potential therapies have been studied to slow progression of ADPKD, none to date have been proven to be both safe and effective in slowing disease progression. Cholesterol-lowering agents called statins have shown promise in the treatment of younger ADPKD patients, reducing inflammation and progression as assessed by kidney growth, but their utility appears to be limited in older populations and those with more advanced chronic kidney disease (CKD). Recent evidence suggests that acidosis, as often seen in patients with worsening CKD and which may enhance CKD progression, limits the effectiveness of statins and enhances their potential toxicity. The investigators thus hypothesize that correction of acidosis along with statin treatment will be a safe and effective therapeutic regimen to slow CKD progression in the adult ADPKD population and improve overall quality of life in these patients. To test this hypothesis, the investigators will conduct a pilot open-label randomized clinical trial in ADPKD patients with estimated GFR \>45 min (Stage 1-3a CKD) comparing three treatment groups: control, pravastatin (40 mg po qd), and pravastatin plus sodium citrate solution (30 mL po total daily dose) over one year. During the study period, through study visits along with serial blood draws and urinary measurements, the investigators will evaluate safety and tolerability of these treatment regimens, follow renal function and investigate the role of these treatments on acidosis, inflammatory and metabolic biomarkers in patients enrolled at an outpatient facility. This study will establish the framework for larger clinical trials in ADPKD. Moreover, if the results of this study suggest safety/tolerability or potential benefits of statins and alkali therapy in this ADPKD population, the investigators will seek extramural funding for a larger clinical trial to test this therapeutic strategy in ADPKD.
NEW MATERIAL:A peptide containing an amino acid sequence of the formula in the molecule. USE:A reagent for researching mechanisms for the promotion of the fractionation, growth and multiplication of cells, the retention of life, the increase of gene manifestation, the induction of proteins or enzymes, etc. PREPARATION:For example, a cDNA library originated from human glyoma is infected on Escherichia coli, mixed with phage and cultured. The cultured product is transferred on a nylon film. DNA coding human nerve growth factor (betaNGF) is synthesized and labeled to prepare a probe. The probe is employed to screen a clone having the DNA coding the peptide of the formula, and the clone is treated with a restriction enzyme, combined with a vector and employed to transform a host. The transformant is cultured in a medium to provide the polypeptide having the amino acid sequence of the formula.
Patients will be randomized to receiving a fixed-dose polypill in addition to other guideline-directed medical therapies prescribed by their physician. Polypill formulations will include rosuvastatin 40 mg, aspirin 81 mg, and prasugrel 10 mg daily or rosuvastatin 40 mg, aspirin 81 mg, and clopidogrel 75 mg.
The invention belongs to the technical field of medicines, in particular to a preparation method of akebia fruit active components and a preparation method of the preparation of the akebia fruit active components and the application in the preparation of antineoplastic medicines of the akebia fruit active components. The preparation method comprises steps as below: smashing the akebia fruit medical materials into coarse powders, soaking the coarse powders in alcohol and heating, refluxing and extracting the akebia fruit medical materials for two to three times, filtering the akebia fruit medical materials, and merging filter liquor. Carrying out vacuum concentration, stewing and centrifugation, and therefore sediment I and supernatant fluid I are obtained. Adjusting the potential of hydrogen (PH) of the supernatant fluid I through alkali to 8 to 14, hydrolyzing the supernatant fluid I for 2 to 8 hours under the temperature of 60 Celsius degrees to 100 Celsius degrees, adding acid to adjust the PH of the supernatant fluid to 3 to 7 after the hydrolyzing, carrying out centrifugation, and therefore the sediment II and the supernatant fluid II after the hydrolyzing are obtained. Merging the sediment I and the sediment II, drying the sediment, and therefore the akebia fruit active components are obtained. The active components have significant antineoplastic activity, and can be used for manufacturing medicines of antineoplastic treatment or auxiliary antineoplastic treatment.
The plasma half-life of fomepizole injection varies with dose, even in patients with normal renal function, and has not been calculated.

Distribution: After intravenous infusion, fomepizole rapidly distributes to total body water. The volume of distribution is between 0.6 L/kg and 1.02 L/kg.

Metabolism: In healthy volunteers, only 1-3.5% of the administered dose of fomepizole (7-20 mg/kg oral and IV) was excreted unchanged in the urine, indicating that metabolism is the major route of elimination. In humans, the primary metabolite of fomepizole is 4-carboxypyrazole (approximately 80-85% of administered dose), which is excreted in the urine. Other metabolites of fomepizole observed in the urine are 4-hydroxymethylpyrazole and the N-glucuronide conjugates of 4-carboxypyrazole and 4-hydroxymethylpyrazole.

Excretion:The elimination of fomepizole is best characterized by Michaelis-Menten kinetics after acute doses, with saturable elimination occurring at therapeutic blood concentrations [100-300 µmol/L, 8.2-24.6 mg/L].

With multiple doses, fomepizole rapidly induces its own metabolism via the cytochrome P450 mixed-function oxidase system, which produces a significant increase in the elimination rate after about 30-40 hours. After enzyme induction, elimination follows first-order kinetics.

Special Populations:
Patients undergoing s stripping operation for varicose veins will be randomized to one of two groups. Group 1 patients will receive propofol anesthesia. Group 2 patients will receive sevoflurane anesthesia. Intraoperative measurements including mean-arterial pressure, heart rate, propofol infusion rate, remifentanil infusion rate, and end-tidal sevoflurane concentration will be taken at 15 minute intervals. Patients in both groups will receive Piritramid as necessary to control pain either intravenously or through patient controlled pump. VAS pain score, mean-arterial pressure, heart rate, nausea will be evaluated at 30 minute intervals during the first four postoperative hours. Piritramid dosage and vomiting will be recorded through the first postoperative morning. Patients will rate pain based on the VAS score for the period between leaving the recovery room and the first postoperative morning
PCT No. PCT/JP97/02255 Sec. 371 Date Dec. 30, 1998 Sec. 102(e) Date Dec. 30, 1998 PCT Filed Jun. 30, 1997 PCT Pub. No. WO98/00420 PCT Pub. Date Jan. 8, 1998Thiophene derivatives represented by the following general formula (I) or pharmaceutically acceptable salts thereof. Said compounds act as an anti-PCP agonist and therefore are useful as psychotropic or antischizophrenic agents and so on. (In the above formula, R1 is a formula -A1-X1-R3; R2 is a formula -A2-X2-R4 or does not exist; B ring is a 7- to 10-membered nitrogen-containing cycloalkyl ring; Ar ring is an aryl or heteroaryl ring; A1, A2 and A3 may be the same or different from one another and each represents a bond or a lower alkylene group; X1 and X2 may be the same or different from each other and each represents a bond or a formula -O-, -S-or the like; R3 and R4 may be the same or different from each other and each represents a hydrogen atom, a cyclic imido group or a lower alkyl group, a cycloalkyl group, an aryl group or an aralkyl group; with the proviso that, when Ar ring is thiazole ring, either one of A1 and A2 is a lower alkylene group. Also, when Ar ring is a benzene ring, a case in which one of R1 and R2 is methyl group or a halogen group and the other is a hydrogen atom is excluded.)
A composition for transdermal delivery of a progestin for progestin hormone therapy is disclosed. Also disclosed is a transdermal delivery device comprising the composition. For progestin-only hormone therapy, the composition contains an anti-oxidant and does not contain an estrogen. For therapy involving a progestin and an estrogen, the composition contains the progestin, the estrogen and an additional anti-oxidant. Methods of improving the stability of progestin-containing compositions comprising oxidative agents are also disclosed. The methods comprise including one or more anti-oxidants in the compositions.
<P>PROBLEM TO BE SOLVED: To provide a solidified powder cosmetic capable of giving a good touch and a beautiful finish, capable of improving cosmetic durability, having a high ultraviolet light protective effect, and good in safety.  <P>SOLUTION: This solidified powder cosmetic contains a fluorine-containing olefin resin powder, a partially crosslinked organopolysiloxane polymer, and an ultraviolet light protective agent. A lubricating effect and a water- and oil-repellent effect of the fluorine-containing olefin resin powder and cushioning properties and the water- and oil-repellent effect of the partially crosslinked organopolysiloxane polymer give the good touch, when the cosmetic is applied to the skin. Further, the effects and properties are synergistically effective for improving dispersibility of an inorganic ultraviolet light-scattering agent which is the ultraviolet light protective agent or uniformizing a coating of an organic ultraviolet light-absorbing agent, so that the cosmetic has a highly ultraviolet light protective effect. Water- and oil-repellent properties belonging to each of the resin powder and the polymer have an effect of maintaining a coating of the cosmetic on the skin for a long time, so as to be more effective for improving the cosmetic durability and keeping the ultraviolet light protective effect. The safety of the obtained composition is good.  <P>COPYRIGHT: (C)2003,JPO